Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
Recruitment status was Not yet recruiting
COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.
Chronic Obstructive Pulmonary Disease
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.|
- myeloperoxidase in induced sputum [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
- MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum. [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
- Lung function (FEV1) [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
- Symptom scores [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||April 2009|
|Estimated Study Completion Date:||January 2010|
|Estimated Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
Doxycycline 100mg daily
Doxycycline tablets, 100mg daily
Placebo Comparator: 2
Placebo tablets 100mg
COPD is a disease characterized by chronic inflammation and irreversible airway obstruction. Chronic inflammation lead to degradation of extracellular matrix and hereby destruction of lung parenchyma. Tetracyclines are known for their anti-inflammatory properties in diseases such as rheumatoid arthritis.
To assess the effect of doxycycline on markers of neutrophilic inflammation and proteolytic activity in induced sputum of stable GOLD II and III COPD patients.
Thirty patients with stable GOLD II COPD.
Placebo versus doxycycline in randomised design.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00857038
|Contact: Wim G Boersma, MDemail@example.com|
|Medical Center Alkmaar||Not yet recruiting|
|Alkmaar, Noord-Holland, Netherlands, 1815JD|
|Contact: Wim G Boersma, MD 0031725482750 firstname.lastname@example.org|